SURF Key Statistics, Chart & Performance
The current stock price of SURF is 1.07 USD. In the past month the price increased by 16.3%. In the past year, price decreased by -21.9%.
SURF Latest News, Press Relases and Analysis
SURF Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About SURF
Company Profile
Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2018-04-19. The firm is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. The Company’s pipeline includes two wholly owned clinical-stage programs targeting IL-27 (SRF388) and SRF114 a preclinical program focused on depleting tumor regulatory T cells through targeting CCR8. In addition, the Company has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562). The Company’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
Company Info
SURFACE ONCOLOGY INC
50 Hampshire Street, 8Th Floor
Cambridge MASSACHUSETTS 02139 US
CEO: J. Jeffrey Goater
Employees: 60
Phone: 16177144096.0
SURFACE ONCOLOGY INC / SURF FAQ
Can you describe the business of SURFACE ONCOLOGY INC?
Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2018-04-19. The firm is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. The Company’s pipeline includes two wholly owned clinical-stage programs targeting IL-27 (SRF388) and SRF114 a preclinical program focused on depleting tumor regulatory T cells through targeting CCR8. In addition, the Company has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562). The Company’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
What is the stock price of SURFACE ONCOLOGY INC today?
The current stock price of SURF is 1.07 USD. The price decreased by -0.93% in the last trading session.
What is the dividend status of SURFACE ONCOLOGY INC?
SURF does not pay a dividend.
What is the ChartMill rating of SURFACE ONCOLOGY INC stock?
SURF has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about SURFACE ONCOLOGY INC (SURF) stock?
11 analysts have analysed SURF and the average price target is 2.43 USD. This implies a price increase of 127.19% is expected in the next year compared to the current price of 1.07.
How many employees does SURFACE ONCOLOGY INC have?
SURFACE ONCOLOGY INC (SURF) currently has 60 employees.
SURF Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SURF. When comparing the yearly performance of all stocks, SURF is one of the better performing stocks in the market, outperforming 78.67% of all stocks.
SURF Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SURF. SURF scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SURF Financial Highlights
Over the last trailing twelve months SURF reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS decreased by -18.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
SURF Forecast & Estimates
11 analysts have analysed SURF and the average price target is 2.43 USD. This implies a price increase of 127.19% is expected in the next year compared to the current price of 1.07.
For the next year, analysts expect an EPS growth of -41.08% and a revenue growth -100% for SURF